Patient Support Program News Today

Thank you all again for coming back today and for tuning in, and i do know that these daily briefings can get tedious, and the information, much of it, sounds the same, so people may start to tune it out, but i can tell you the situation is changing, it is evolving, and the information we are putting out is important. Just because the social distancing and hygiene guidance and the stay at home order stays in place after day doesnt mean we shouldnt talk about those things because that will be the...

Trying to get through this Public Health emergency with the fewest amount of cases and the lowest death total. Corey he thank dr. Bert. He has been a practicing physician for decades, although he does not look that old. He is the chief chief medical officer for dillard university. He is also working with the state of Public Health. And it is great to have him here today. He will take questions and have some prepared comments after i am finished. The doctory have from the apart department of heal...

Approval across ESA ineligible and ESA relapsed/refractory patients with LR-MDS with transfusion-dependent anemia, regardless of ring sideroblast status Durable and sustained red blood cell...

In recognition of World Multiple Sclerosis Day, Roche Pakistan Limited held a panel discussion to raise awareness about Multiple Sclerosis (MS) in

12.01.2024 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of ...

KEYTRUDA is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients Approval marks third FDA-approved indication for KEYTRUDA in cervical cancer and...

RAHWAY, N.J.--(BUSINESS WIRE)--Dec 15, 2023--

The U.S. government is winding down control of the COVID-19 therapeutics distribution and moving towards commercialization, much like with vaccines earlier in the fall. The Administration for Strategic Preparedness and Response developed this resource outlining the transition plan. Merck and Pfizer are releasing additional information as well.

The U.S. government is winding down control of the COVID-19 therapeutics distribution and moving towards commercialization, much like with vaccines earlier in the fall. The Administration for Strategic Preparedness and Response developed this resource outlining the transition plan. Merck and Pfizer are releasing additional information as well.

There is evidence to show patient support programs have been used to encourage use of a company’s drug, which is problematic, doctors say